Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease.

de Bruyn M, Machiels K, Vandooren J, Lemmens B, Van Lommel L, Breynaert C, Van der Goten J, Staelens D, Billiet T, De Hertogh G, Ferrante M, Van Assche G, Vermeire S, Opdenakker G, Schuit F, Rutgeerts P, Arijs I.

Inflamm Bowel Dis. 2014 Feb;20(2):339-52. doi: 10.1097/01.MIB.0000438430.15553.90.

PMID:
24378596
2.

Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.

Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, Leemans P, Cleynen I, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P.

PLoS One. 2009 Nov 24;4(11):e7984. doi: 10.1371/journal.pone.0007984.

3.

Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease.

Meijer MJ, Mieremet-Ooms MA, van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, van Hogezand RA, Lamers CB, Verspaget HW.

Inflamm Bowel Dis. 2007 Feb;13(2):200-10.

PMID:
17206679
4.

Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.

Biancheri P, Brezski RJ, Di Sabatino A, Greenplate AR, Soring KL, Corazza GR, Kok KB, Rovedatti L, Vossenkämper A, Ahmad N, Snoek SA, Vermeire S, Rutgeerts P, Jordan RE, MacDonald TT.

Gastroenterology. 2015 Nov;149(6):1564-1574.e3. doi: 10.1053/j.gastro.2015.07.002. Epub 2015 Jul 11.

5.

High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF-α in the mucosa of patients with inflammatory bowel diseases.

Franzè E, Caruso R, Stolfi C, Sarra M, Cupi ML, Ascolani M, Sedda S, Antenucci C, Ruffa A, Caprioli F, MacDonald TT, Pallone F, Monteleone G.

Inflamm Bowel Dis. 2013 Mar;19(3):501-11. doi: 10.1097/MIB.0b013e31828028e8.

PMID:
23429442
6.

Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.

Caprioli F, Bosè F, Rossi RL, Petti L, Viganò C, Ciafardini C, Raeli L, Basilisco G, Ferrero S, Pagani M, Conte D, Altomare G, Monteleone G, Abrignani S, Reali E.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):729-39. doi: 10.1097/MIB.0b013e318280292b.

PMID:
23448791
7.

Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium.

Pedersen G, Saermark T, Kirkegaard T, Brynskov J.

Clin Exp Immunol. 2009 Feb;155(2):257-65. doi: 10.1111/j.1365-2249.2008.03836.x.

8.

Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns Disease.

Sena A, Grishina I, Thai A, Goulart L, Macal M, Fenton A, Li J, Prindiville T, Oliani SM, Dandekar S, Goulart L, Sankaran-Walters S.

PLoS One. 2013 Oct 10;8(10):e76969. doi: 10.1371/journal.pone.0076969. eCollection 2013.

9.

Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.

Ierardi E, Giorgio F, Zotti M, Rosania R, Principi M, Marangi S, Della Valle N, De Francesco V, Di Leo A, Ingrosso M, Panella C.

J Clin Pathol. 2011 Nov;64(11):968-72. doi: 10.1136/jcp.2010.086892. Epub 2011 Sep 22.

PMID:
21945924
10.

IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease.

Su J, Chen T, Ji XY, Liu C, Yadav PK, Wu R, Yang P, Liu Z.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):720-8. doi: 10.1097/MIB.0b013e3182802a76.

PMID:
23429464
11.

Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.

Veltkamp C, Anstaett M, Wahl K, Möller S, Gangl S, Bachmann O, Hardtke-Wolenski M, Länger F, Stremmel W, Manns MP, Schulze-Osthoff K, Bantel H.

Gut. 2011 Oct;60(10):1345-53. doi: 10.1136/gut.2010.217117. Epub 2011 Apr 1.

PMID:
21459928
12.
13.

Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.

Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, Van Den Bosch F, Veys EM, De Keyser F, Baeten D.

Arthritis Rheum. 2004 Sep;50(9):2942-53.

14.

Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.

Perrier C, Arijs I, Staelens D, Breynaert C, Cleynen I, Covens K, Ferrante M, Van Assche G, Vermeire S, de Hertogh G, Schuit F, Rutgeerts P, Ceuppens JL.

Immunology. 2013 Jan;138(1):47-56. doi: 10.1111/imm.12014.

15.

Expression of Toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2.

Østvik AE, Granlund AV, Torp SH, Flatberg A, Beisvåg V, Waldum HL, Flo TH, Espevik T, Damås JK, Sandvik AK.

Clin Exp Immunol. 2013 Sep;173(3):502-11. doi: 10.1111/cei.12136.

16.

Increased expression of IL-16 in inflammatory bowel disease.

Seegert D, Rosenstiel P, Pfahler H, Pfefferkorn P, Nikolaus S, Schreiber S.

Gut. 2001 Mar;48(3):326-32.

17.

AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease.

Bhol KC, Tracey DE, Lemos BR, Lyng GD, Erlich EC, Keane DM, Quesenberry MS, Holdorf AD, Schlehuber LD, Clark SA, Fox BS.

Inflamm Bowel Dis. 2013 Oct;19(11):2273-81. doi: 10.1097/MIB.0b013e3182a11958.

18.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
19.

Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.

Abraham NS, Richardson P, Castillo D, Kane SV.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1281-7. doi: 10.1016/j.cgh.2013.06.004. Epub 2013 Jun 19.

PMID:
23792295
20.

Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.

Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW.

Curr Med Res Opin. 2005 Nov;21(11):1741-54.

PMID:
16307694
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk